RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

If confirmed as the HHS Secretary by the US Senate, RFK Jr will oversee federal agencies that dictate healthcare policy in ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a ...

SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.